Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression

  • J Clin Invest. 2023 Feb 16;e162324. doi: 10.1172/JCI162324.
Ipshita Nandi  1 ,  Harvey W Smith  1 ,  Virginie Sanguin-Gendreau  1 ,  Linjia Ji  1 ,  Alain Pacis  1 ,  Vasilios Papavasiliou  1 ,  Dongmei Zuo  1 ,  Stella Nam  1 ,  Sherif S Attalla  1 ,  Sung Hoon Kim  2 ,  Sierra Lusson  1 ,  Hellen Kuasne  1 ,  Anne-Marie Fortier  1 ,  Paul Savage  1 ,  Constanza Martinez Ramirez  1 ,  Morag Park  1 ,  John A Katzenellenbogen  2 ,  Benita S Katzenellenbogen  3 ,  William J Muller  1
Affiliations
  • 1. Goodman Cancer Institute, McGill University, Montreal, Canada.
  • 2. Department of Chemistry, University of Illinois Urbana-Champaign, Urbana, United States of America.
  • 3. Department of Molecular and Integrative Physiology, University of Illinois Urbana-Champaign, Urbana, United States of America.
Abstract

Activation of the tyrosine kinase c-Src promotes Breast Cancer progression and poor outcomes, yet the underlying mechanisms are incompletely understood. Here, we show that deleting c-Src abrogates the activity of Forkhead Box M1 (FOXM1), a master transcriptional regulator of the cell cycle, in a genetically engineered model mimicking the Luminal B molecular subtype of Breast Cancer. By phosphorylating it on two tyrosine residues, c-Src stimulates the nuclear localization of FOXM1 and the expression of its target genes, including key regulators of G2-M cell cycle progression as well as c-Src itself. This positive feedback loop drives proliferation in genetically engineered and patient-derived models of Luminal B-like Breast Cancer. Targeting this mechanism, including through novel compounds that destabilize the FOXM1 protein, induces G2-M cell cycle arrest and Apoptosis, blocking tumor progression and impairing metastasis. We identify a positive correlation between FOXM1 and c-Src expression in human Breast Cancer and show that the expression of FOXM1 target genes predicts poor outcomes and associates with the Luminal B subtype, which responds poorly to approved therapies. These findings indicate that a regulatory network centered on c-Src and FOXM1 is a targetable vulnerability in aggressive luminal breast cancers.

Keywords
Breast cancer; Cell cycle; Mouse models; Oncology; Therapeutics.
Products